The hTC, − 279/+ 5, and Brms1 promoters all display significantly higher levels of killing by p53-Bad* in cancer cells versus normal cells (Figs. 9, 10 and 11), while the CMV promoter consistently shows no significant difference between killing by p53-Bad* in cancer versus normal cells. This evidence concerns the gene BAD and cancer.